Johnson & Johnson Earnings Summary — Q1 2026

• Revenue increased by 9.91% year-over-year to $24.06 billion, demonstrating strong organic growth post-Kenvue spinoff.
• Net income of $5.24 billion shows stability compared to the prior quarter, though it is down YoY against a distorted Q1 2025 comparison.
• Operating income rose sequentially to $6.33 billion as the company improved its focus on high-margin Pharmaceuticals and MedTech.
• Research & Development investment remains a priority at $3.56 billion to fuel the immunology and oncology pipelines.
• The successful separation of the Kenvue consumer health division has effectively pivoted J&J toward higher-growth healthcare segments.
• Litigation remains a persistent headwind, specifically regarding talc and opioid settlements, which often result in non-operating charges.

Management is focusing capital deployment on the expansion of MedTech robotic surgery and maintaining a robust pharmaceutical pipeline to offset upcoming patent cliffs for assets like Stelara.

Stable

The transition to a more focused innovation-driven specialist is proceeding as planned, with steady revenue growth offsetting litigation concerns.

The company expects to leverage its 'AAA' credit rating and strong operating cash flow to fund R&D and strategic acquisitions in the oncology segment while managing regulatory headwinds from the Inflation Reduction Act.